Metabolomic and proteomic analyses for pharmacotherapy
- At: 2010 FIP Congress in Lisbon (Portugal)
- Type: Presentation
- By: TANIGAWARA, Yusuke (Keio University, School of Medicine, Tokyo, Japan)
The individualization of pharmacotherapy based on each patient's responsiveness to drugs is required to improve clinical outcome, particularly for life-threatening cancer chemotherapy. We have studied exploratory genomic, proteomic and metabolomic analyses to discover potential biomarkers that can predict responders/non-responders to cancer.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.